Is the combined mupirocin‑betamethasone ointment safe for a patient with glucose‑6‑phosphate dehydrogenase (G6PD) deficiency?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 28, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Mupirocin-Betamethasone Ointment is Safe for G6PD Deficiency

Yes, mupirocin-betamethasone ointment is safe to use in patients with G6PD deficiency. Neither component of this topical combination poses a hemolytic risk in G6PD-deficient individuals.

Evidence-Based Rationale

Mupirocin Safety Profile

Mupirocin is a topical antibiotic with no documented association with hemolysis or oxidative stress in G6PD-deficient patients 1. The FDA drug label for mupirocin lists only local adverse reactions (burning, stinging, itching, rash) with no warnings regarding G6PD deficiency 1.

Betamethasone Safety Profile

Topical corticosteroids like betamethasone work through anti-inflammatory mechanisms that do not involve oxidative pathways. There is no evidence linking topical corticosteroids to hemolysis in G6PD deficiency.

Comprehensive G6PD Medication Review

The most rigorous evidence-based reviews of medications in G6PD deficiency identify only seven medications with solid evidence for prohibition: dapsone, methylthioninium chloride (methylene blue), nitrofurantoin, phenazopyridine, primaquine, rasburicase, and tolonium chloride 2. Neither mupirocin nor betamethasone appear on this list.

The 2023 Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline classifies medications by risk level (high, medium, low-to-no risk) for G6PD-deficient patients 3. Topical antibiotics and corticosteroids are not included among medications requiring precautions.

Important Distinction: Topical vs. Systemic Dapsone

While systemic dapsone is absolutely contraindicated in G6PD deficiency due to its potent oxidant effects and risk of severe hemolysis 4, 5, topical dapsone gel 5% has been specifically studied and shown to be safe in G6PD-deficient patients, with no risk of hemolytic anemia 6. This demonstrates that topical formulations generally pose minimal systemic absorption and oxidative risk.

Clinical Application

  • Use the combination ointment without hesitation in G6PD-deficient patients
  • No special monitoring is required beyond standard assessment for local skin reactions
  • The only contraindication listed for mupirocin is hypersensitivity to the drug itself 1

The confusion around G6PD deficiency often stems from outdated or overly cautious medication lists. Real-world data from over 31,000 G6PD-deficient patients showed that many previously suspected medications have been prescribed safely without causing hemolysis 7.

References

5
Guideline

guidelines of care for the management of acne vulgaris.

Journal of the American Academy of Dermatology, 2016

Related Questions

Can carbocysteine be given to a patient with glucose‑6‑phosphate dehydrogenase (G6PD) deficiency?
Are co-amoxiclav (amoxicillin + clavulanic acid) and mefenamic acid safe to use in a patient with glucose‑6‑phosphate dehydrogenase (G6PD) deficiency?
Is amoxicillin safe for children with glucose‑6‑phosphate dehydrogenase (G6PD) deficiency?
Which medications are contraindicated for a child with glucose‑6‑phosphate dehydrogenase (G6PD) deficiency?
Which medications should be avoided in children with glucose-6-phosphate dehydrogenase (G6PD) deficiency?
In a 59-year-old woman presenting with altered mental status, severe dehydration, excessive thirst, polyuria, hyperglycemia (>1000 mg/dL), HbA1c 14%, hypernatremia, high serum osmolality, and concentrated urine, what is the most likely cause of her symptoms: arginine vasopressin resistance, central diabetes insipidus, hypovolemic hyponatremia, or primary polydipsia?
Which intravenous medications can be given for transaminitis?
How much oral rehydration solution should be given to a 9‑week‑old infant with diarrhea?
In a 55-year-old man with hypertension, type 2 diabetes mellitus, and remote subarachnoid hemorrhage (treated with aneurysmal clipping) who is postoperative day 1 after complex abdominal surgery and now presents with agitation and disorientation, normal vital signs, normal laboratory studies, and a non‑contrast head CT without acute findings, which diagnostic test should be ordered next?
In a patient with hyperthyroidism on methimazole 20 mg daily who now has TSH <0.01 mIU/L and FT4 18 pmol/L, should the methimazole dose be increased for better control?
How should I manage a 19‑year‑old female with recent viral upper‑respiratory symptoms and a respiratory culture growing Enterobacter cloacae complex that is resistant to amoxicillin‑clavulanate and cefoxitin but susceptible to cefepime, ertapenem, gentamicin, levofloxacin, tetracycline, tobramycin, and trimethoprim‑sulfamethoxazole?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.